Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.42 |
| ▸ | CES2 | O00748 | 6/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8805740 | 0.99 | MAPK1 (0.48) | ALDH1A1CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL9719342 | 0.87 | ALOX5 (0.47) | ALDH1A1CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL9719340 | 0.85 | GSK3B (0.51) | CYP1A2CYP3A4CYP2C19LMNASMN1; SMN2 | |
| SCHEMBL8805922 | 0.82 | LMNA (0.39) | ALDH1A1CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL29158505 | 0.81 | ALDH1A1 (0.55) | ALDH1A1CYP1A2CYP3A4CYP2C19LMNA | |
| SCHEMBL9719345 | 0.80 | ROCK2 (0.51) | ALDH1A1CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL9719389 | 0.80 | LMNA (0.44) | ALDH1A1CYP1A2CYP3A4CYP2C19LMNA | |
| SCHEMBL8806746 | 0.79 | L3MBTL1 (0.39) | ALDH1A1CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL17300510 | 0.78 | EP300 (0.50) | ALDH1A1CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL4687956 | 0.78 | ALOX5 (0.50) | ALDH1A1CYP1A2CYP3A4CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000002549-A2 | COMPOSITION FOR AND METHOD OF TREATING NEUROLOGICAL DISORDERS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-01-20 | — | — | WO | claimed |
| WO-1995027489-A1 | COMPOSITION FOR TREATING NEUROLOGICAL DISORDERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-10-19 | — | — | WO | claimed |
| EP-1036175-B1 | HUMAN BRAIN DERIVED KCNQ2 POTASSIUM CHANNEL | ASTRAZENECA AB (SE) | 2008-04-09 | — | — | EP | disclosed |
| US-20060183105-A1 | Human brain-derived tissue-specific potassium channel | AIYAR JAYASHREE | 2006-08-17 | — | — | US | disclosed |
| US-6893858-B2 | Human kcnq5 potassium channel, methods and compositions thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-17 | — | — | US | disclosed |
| US-20050064491-A1 | Human KCNQ5 potassium channel, methods and compositions thereof | DWORETZKY STEVEN I (US) | 2005-03-24 | — | — | US | disclosed |
| CN-1179962-C | Azaindolizinone derivatives and cerebral function improvers containing the same as the active ingredient | ������ҩ��ҵ��ʽ���� | 2004-12-15 | — | — | CN | disclosed |
| US-20040038890-A1 | Human voltage-gated potassium channel subunit | AIYAR JAYASHREE (US) | 2004-02-26 | — | — | US | disclosed |
| EP-1290167-A1 | HUMAN KCNQ5 POTASSIUM CHANNEL, METHODS AND COMPOSITIONS THEREOF | Bristol-Myers Squibb Company (US) | 2003-03-12 | — | — | EP | disclosed |
| CN-1377351-A | Azaindolizinone derivatives and cerebral function improvers containing the same as the active ingredient | ZENYAKU KOGYO KK (JP) | 2002-10-30 | — | — | CN | disclosed |
| US-20020040000-A1 | Human kcnq5 potassium channel, methods and compositions thereof | BRISTO-MYERS SQUIBB COMPANY | 2002-04-04 | — | — | US | disclosed |
| WO-1999031232-A1 | HUMAN BRAIN DERIVED KCNQ2 POTASSIUM CHANNEL | ASTRAZENEKA UK LIMITED (GB) | 1999-06-24 | — | — | WO | disclosed |
| EP-0623127-B1 | NOVEL NEUROTRANSMITTER RELEASERS USEFUL FOR COGNITION ENHANCEMENT | DU PONT MERCK PHARMA (US) | 1997-04-02 | — | — | EP | disclosed |
| US-5532247-A | ACENAPHTHENES SUBSTITUTED IN THE 1-POSITION BY PYRIDYLMETHYL OR FLUOROPYRIDYLMETHYL; TREATING COGNITIVE OR NEUROLOGICAL DYSFUNCTION THEREWITH | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-07-02 | — | — | US | disclosed |
| WO-1995027489-A1 | COMPOSITION FOR TREATING NEUROLOGICAL DISORDERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-10-19 | — | — | WO | disclosed |
| EP-0664810-A1 | 3,3-DISUBSTITUTED TRI- AND TETRACYCLIC INDOLIN-2-ONES USEFUL FOR THE TREATMENT OF COGNITIVE DISORDERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-08-02 | — | — | EP | disclosed |
| US-5434264-A | α,α-disubstituted aromatics and heteroaromatics as cognition enhancers | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-07-18 | — | — | US | disclosed |
| EP-0636132-A1 | SUBSTITUTED NITROGEN CONTAINING SPIRO COMPOUNDS FOR USE IN TREATING COGNITIVE DEFICITS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-02-01 | — | — | EP | disclosed |
| WO-1993021185-A1 | SUBSTITUTED NITROGEN CONTAINING SPIRO COMPOUNDS FOR USE IN TREATING COGNITIVE DEFICITS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-10-28 | — | — | WO | disclosed |
| WO-1992000760-A1 | METHOD OF TREATING NEUROLOGICAL DYSFUNCTION USING NEUROTRANSMITTER ENHANCES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-01-23 | — | — | WO | disclosed |